Furthermore, as insulin secretion in T2D can be enhanced by drugs that bypass the metabolic steps (such as sulphonylureas or GLP-1-based therapies), it appears insulin content is also not limiting and thus that metabolic failure plays a critical role in diabetes development. This evidence concerns the gene INS and type 2 diabetes mellitus.